Trump nominates pharma insider Azar to lead HHS

Share

Alex Azar TrumpThe Trump administration today nominated Alex Azar, who spent nearly 10 years at Eli Lilly (NYSE:LLY) after working in the second Bush administration, as secretary of the U.S. Health & Human Services Dept.

The former HHS head, Dr. Tom Price, resigned in September after days of fending off criticism over chartered flights he took on the public dime. Price racked up roughly $1 million in private and government air travel in just seven months, according to Politico.

“It’s a great pick for where the agency is right now,” Lanhee Chen, who worked with Azar on Mitt Romney’s 2012 presidential campaign, told the website. “I don’t think anybody can question his credentials from an experience perspective.”

Get the full story on our sister site MassDevice.

 

How do you know your technology is disruptive enough to break conventional wisdom?

textadimage Stan Rowe knows a little something about bringing disruptive technology to market. The current Edwards Lifesciences CSO was in on the ground floor of two of medtech's most disruptive treatments, stents and transcatheter aortic valve replacement.

On December 12th, Rowe will sit down with MassDevice editor Brad Perriello for a long ranging discussion about the inside story on how these technologies came to market and what Rowe learned along the way.


Register now with the code "TAVR" and save 15% today.

Speak Your Mind

*